{"company":{"slug":"breye-therapeutics","name":"Breye Therapeutics","stage":"series-a","industry":"bio-health","subcategory":null,"sector":"Biopharma, Biotechnology, Life Science, Medical, Pharmaceutical","description":"Breye Therapeutics develops oral medicines for retinal diseases, with a focus on diabetic retinopathy and age-related macular degeneration.","crypto":false,"first_seen_at":"2026-10-04T09:41:51.158Z","hq_city":"Hørsholm","hq_country":"Denmark","founded_year":null,"website":"https://breye.com","x_handle":null,"followers":null,"logo":"https://recentfunding.com/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzcwNTMyZWNlMWIyZTRkZmNhMzU5ZWFlODU2ZWRhYmJj","amount_usd":"76646250.00","announced_at":"2026-09-29T00:00:00.000Z","raise_source_url":"https://european-biotechnology.com/latest-news/breye-raises-e67-5m-for-diabetic-eye-disease-trial-with-novo-holdings-backing/","raise_publisher":null,"raise_provider":null,"sources":[],"investors":["Catalyze Capital","Export and Investment Fund","Innovestor","Mission BioCapital","Modi Ventures","Novo Holdings","Pappas Capital","Sound Bioventures","The Ljungstrom Family Office","Vaekstfonden"],"flagged":false,"flagged_at":null,"source_links":{},"x_created_at":null,"domain_created_at":"2005-05-04","smart_follows":null,"days_early":null,"new_follows_7d":null,"trending_rank":null,"team_size":null,"team_source_url":null,"categories":["health-bio"]},"rounds":[{"stage":"series-a","amount_usd":"76646250.00","valuation_usd":null,"announced_at":"2026-09-29T00:00:00.000Z","source_url":"https://european-biotechnology.com/latest-news/breye-raises-e67-5m-for-diabetic-eye-disease-trial-with-novo-holdings-backing/","source_publisher":null,"source_provider":null}],"founders":[{"name":"Ulrik Mouritzen","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2RzbHRqN2VyMG5ka3p3ZGJkaGZx","role":"Founder","source_url":null,"other_companies":[]},{"name":"Jim Van heusden","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL3YxMzk3MTgzMzQxLzI4YWY0N2MyZTk0ZmUyYTI3YWM3YWVkMmRkOGYzMzA1LmpwZw","role":"Board member","source_url":null,"other_companies":[]},{"name":"Johan Kördel","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL3YxMzk3MTg3NzEwLzNmMTgzM2FjNWU2NmNjMGVjMTQwOTI0ZTZhOTkxMmE1LmpwZw","role":"Board member","source_url":null,"other_companies":[]},{"name":"Jørgen Søberg Petersen","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2t6Z3FpZGdxdXp1MjIxdXhrdXN3","role":"Board member","source_url":null,"other_companies":[]},{"name":"Lukas Ljungstrom","x_handle":null,"linkedin_url":null,"avatar":null,"role":"Board member","source_url":null,"other_companies":[]},{"name":"Robert Blazej","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzVmODk1YjUzNTgyMDRjMmE5YWM2NzY1YjI0MDNlYTZk","role":"Board member","source_url":null,"other_companies":[]}]}